Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Alnylam Pharmaceuticals, Inc. ALNY

Healthcare — Biotechnology

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
53.75
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell 5 2 — 5 6 10 1 — 1 — — —
Insider Ownership
0.18%

Capital & Financial Ratios

Market Cap
32,860.00
Revenue
4,804.18
Net Income
774.71
Free Cash Flow
819.87
Net Debt
(2,297.17)
Current Ratio
3.05
Debt/Equity
0.75
P/E ratio
43.32
P/S ratio
6.66
P/B ratio
23.64
Past 5Y EPS Growth
23.11%
This Y EPS Growth
186.44%
Next Y EPS Growth
50.99%
Next 5Y EPS Growth
75.12%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
2.52%
total individual payouts
2025 ‡‡‡
2024 ‡‡‡
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2017 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 2,439.38 2,694.50 2,908.48 3,308.15
Receivables 327.79 405.31 777.57 912.74
Inventory 89.15 78.51 82.72 97.11
Other — — — —
2,982.70 3,295.29 4,050.66 4,620.17
2023 2024 2025 Q'26
Payables 55.52 88.42 115.72 108.02
ST’ Debt — — — —
Other 54.99 206.80 220.07 258.57
967.79 1,186.27 1,466.35 1,512.51
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡ ‡‡‡ ‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 1,167.18 1,290.95 — —
—
’25 594.19 773.69 1,249.03 1,097.03
3,713.94
’24 494.33 659.83 500.92 593.17
2,248.24
’23 319.29 318.75 750.53 439.72
1,828.29
’22 213.26 224.82 264.31 335.03
1,037.42
’21 177.57 220.55 187.63 258.54
844.29
’20 99.48 103.96 125.85 163.56
492.85
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 70.50 326.72 — —
—
’25 (120.31) 129.81 351.03 163.56
524.08
’24 (81.51) 124.16 43.71 (94.66)
(8.31)
’23 (166.47) (58.99) 359.41 (29.79)
104.16
’22 (171.19) (122.82) (115.28) (131.98)
(541.27)
’21 (235.66) (121.86) (134.04) (150.14)
(641.69)
’20 (246.16) (135.33) (110.33) (123.14)
(614.96)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 48.67 292.04 — —
—
’25 (129.28) 115.51 338.89 140.26
465.38
’24 (94.49) 116.14 39.52 (103.76)
(42.59)
’23 (180.37) (74.90) 342.32 (45.10)
41.95
’22 (189.05) (138.87) (131.79) (153.61)
(613.33)
’21 (252.84) (133.10) (160.10) (172.03)
(718.06)
’20 (265.78) (151.99) (122.74) (144.81)
(685.32)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 1.51 1.21 — —
—
’25 (0.44) (0.51) 1.84 0.82
2.33
’24 (0.52) (0.13) (0.87) (0.65)
(2.18)
’23 (1.40) (2.21) 1.15 (1.10)
(3.52)
’22 (2.00) (2.29) (3.32) (1.68)
(9.30)
’21 (1.71) (1.61) (1.72) (2.16)
(7.20)
’20 (1.62) (1.56) (2.18) (2.09)
(7.46)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡‡

Recommendation Rating

1.6
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 117.58 148.10 141.98 205.87 — — —
Low Price
‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 242.97 242.39 304.39 495.55 — — —
High Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2,002 2,100 2,230 2,770 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.52 0.87 1.01 1.34 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,037.42 1,828.29 2,248.24 3,713.94 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 83.73% 83.02% 85.62% 81.64% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1,126.99) (433.52) (377.37) 323.15 ‡‡‡‡‡ — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (108.63%) (23.71%) (16.79%) 8.70% ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1,131.16) (440.24) (278.16) 313.75 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 44.47 54.05 56.67 55.66 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 8.53 14.64 17.61 28.35 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ (9.30) (3.52) (2.18) 2.39 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (4.45) 0.83 (0.07) 4.00 ‡‡‡‡ — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.59) (0.50) (0.27) (0.45) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (5.04) 0.34 (0.33) 3.55 — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.30) (1.77) 0.53 6.02 ‡‡‡‡‡ — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 121.69 124.91 127.65 131.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 220.92 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 27.40 13.32 13.36 14.03 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.00 0.00 447.73 66.01 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 26.35 12.59 12.66 13.54 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (44.56) 548.70 (668.10) 108.04 — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (541.27) 104.16 (8.31) 524.08 ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (72.06) (62.21) (34.28) (58.70) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (613.33) 41.95 (42.59) 465.38 ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,924.33 2,014.91 2,109.01 2,584.31 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,098.94 1,020.78 1,024.62 1,007.78 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1,093.46) (1,418.61) (1,669.88) (1,900.70) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (158.22) (220.64) 67.09 789.18 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (31.47%) (11.94%) (6.89%) 6.82% ‡‡‡‡‡ — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡ 0.00% 0.00% 0.00% 0.00% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (526.14%) 232.40% 362.29% 73.28% ‡‡‡‡ — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Alnylam Pharmaceuticals (ALNY) has evolved from an RNAi pioneer into a revenue juggernaut, with blockbuster drugs like Onpattro, Givlaari, Oxlumo, and Amvuttra fueling a staggering 3,780% revenue surge from $47 million in 2016 to $1.83 billion in 2023. Projections dazzle: revenues nearly tripling to $7.29 billion by 2027, alongside a dramatic profitability pivot—from peak losses of $1.13 billion in 2022 to $1.57 billion profits in 2027. Gross margins near 85%, skyrocketing revenue per employee, and positive free cash flow underscore operational mastery, while a fortress balance sheet boasting $1.7 billion in net cash de-risks the growth story amid modest share dilution.

Yet valuation screams opportunity: forward P/E compressing from 139x to 28x by 2027, PS ratios derated 90% historically, and analyst targets implying 14-80% upside on pipeline catalysts like ATTR-CM expansions and Inclisiran ramps. Routine insider sells via 10b5-1 plans amid stock peaks are noise in this bullish backdrop, not red flags. With $5B+ potential from Phase 3 assets and first-mover RNAi dominance, ALNY’s trajectory hints at 2-3x returns—data-driven disruption begging for a closer look.

Read full commentary →

Alnylam Pharmaceuticals, Inc. (ALNY) Latest News

News by impact score

Fine-tune

19 Sep

4 www.marketbeat.com, 9:01 PM
Alnylam Pharmaceuticals advances Zilebesiran toward twice-yearly blood pressure control via the ZENITH trial. Zilebesiran ZENITH trial marks major pipeline progress that can shift Alnylam trajectory and investor outlook.

10 Sep

3 , 7:44 AM
Alnylam Pharmaceuticals (ALNY) stock declined following developments that weighed on investor sentiment regarding its pipeline and financial outlook. Stock decline tied to company-specific events can influence near-term sentiment without fundamentally shifting long-term trajectory.

31 Aug

4 , 11:40 AM
Oppenheimer states Alnylam's latest Nucresiran data strengthens TRITON-CM outlook. Positive analyst view on Nucresiran data boosts Alnylam drug prospects and stock trajectory.

30 Aug

3 , 8:23 AM
Alnylam Pharmaceuticals presented new data at ESC Congress 2026 reinforcing the strength of RNAi-powered TTR silencing across ATTR-CM patient populations and treatment settings. Positive clinical data on core ATTR-CM therapy presented at major cardiology congress can moderately lift investor sentiment and support near-term performance.

25 Aug

4 , 1:36 PM
BridgeBio Q2 sales rose 120% driven by Attruby commercial momentum. Attruby sales surge signals rising competition that can erode ALNY ATTR market share.

24 Aug

4 , 3:09 PM
Alnylam Pharmaceuticals evaluates expanded HELIOS-B and Zilebesiran data as potential drivers for sustained cardiovascular market leadership. Expanded HELIOS-B and Zilebesiran data represent major product and strategic advances that could reshape Alnylam's cardiovascular trajectory and investor sentiment.

3 , 5:10 PM
Alnylam Pharmaceuticals heads to ESC with new data, raising questions on whether ALNY stock is a bargain. New data presentation at ESC may moderately affect ALNY pipeline perception and short-term market sentiment.

3 , 8:33 AM
Alnylam Pharmaceuticals will present new data at ESC Congress 2026 on RNAi-powered TTR silencing strength and hypertension program progress. Pipeline data presentation at major medical congress supports continued innovation in core TTR and hypertension programs.

16 Aug

3 www.fool.com, 6:01 AM
Alnylam stock sell-off appears excessive, with investors overlooking key positive factors in the company's outlook and pipeline. Optimistic reassessment of overlooked positives may lift near-term sentiment and valuation without altering core trajectory.

3 Aug

4 transcript www.fool.com, 9:54 PM
Alnylam Pharmaceuticals Inc. conducted its Q2 2026 earnings conference call covering financial results, operational updates and forward outlook. Quarterly earnings calls deliver financial results and guidance that frequently drive immediate stock price moves and alter investor expectations.

31 Jul

4 , 11:25 AM
Alnylam Pharmaceuticals' Q2 earnings missed estimates, triggering a 28% stock drop and a cut to 2026 sales guidance. Q2 miss plus reduced 2026 sales view drove immediate 28% stock plunge and signals major near-term pressure on operations and investor outlook.

30 Jul

4 transcript , 5:04 PM
Alnylam Pharmaceuticals reported Q2 2026 results with Amvuttra exceeding $1 billion in sales, underscoring strong demand for its RNAi therapeutic amid expanding market adoption. Amvuttra surpassing $1 billion establishes a major commercial milestone that can accelerate revenue trajectory and investor confidence.

4 transcript www.marketbeat.com, 10:04 AM
Alnylam Pharmaceuticals Q2 earnings call highlighted financial results, pipeline progress, and company guidance. Q2 earnings call details can significantly influence stock price and market perception through revealed financials and strategies.

3 transcript www.fool.com, 11:20 PM
Alnylam Pharmaceuticals, Inc. held its Q2 2026 earnings call to review financial results, operational updates, and future outlook. Quarterly earnings calls deliver performance data and guidance that can shift near-term stock sentiment without altering long-term strategy.

3 www.biopharmadive.com, 12:12 PM
Alnylam Pharmaceuticals shares plunge after earnings deliver dual negative surprises that hit both financial results and forward outlook. Earnings shortfalls trigger immediate stock drop and may pressure near-term sentiment without fundamentally shifting long-term trajectory.

3 , 9:35 AM
Alnylam Pharmaceuticals (ALNY) missed Q2 earnings and revenue estimates. Q2 earnings and revenue miss pressures near-term stock price and investor expectations for Alnylam.

29 Jul

4 , 7:12 PM
Alnylam Pharmaceuticals (ALNY) could be 34% undervalued following an update on its Alzheimer’s pipeline. Alzheimer’s pipeline progress signals major strategic expansion that can shift company trajectory and investor views.

4 , 2:10 PM
Alnylam Pharmaceuticals shares rose 6.3% after presenting new RNAi data for Alzheimer’s and reporting over $1B in quarterly revenue. New Alzheimer’s RNAi data plus $1B-plus revenue establish major growth catalyst and market expansion for Alnylam.

28 Jul

3 , 4:16 AM
Alnylam posted its strongest quarter on record with revenue and pipeline progress but stock valuation stayed flat due to concerns over long-term profitability and competition. Strong quarterly results failed to lift valuation because of ongoing investor doubts on sustained growth.

15 Jul

3 , 3:30 AM
Alnylam Pharmaceuticals presented advancements in neuroscience programs at AAIC 2026, highlighting RNAi applications for neurological diseases. Conference highlights on neuroscience pipeline progress indicate moderate effects on Alnylam future positioning and sentiment.

14 Jul

3 , 10:50 AM
BofA Securities states Alnylam Pharmaceuticals' Q2 results will set the 2026 revenue outlook. Linkage of Q2 results to 2026 revenue forecast can moderately shape investor expectations for long-term performance.

13 Jul

4 www.marketbeat.com, 12:25 PM
Phase 3 failure triggered opposing stock moves among biotech companies, with clear winners and losers including Alnylam Pharmaceuticals. Phase 3 failure directly hits Alnylam pipeline progress and valuation.

10 Jul

4 , 3:13 PM
Rival ATTR-CM trial failure combined with Alnylam's new AI deals raises questions over whether the company's investment case has changed. Rival trial failure and new AI deals represent major competitive and strategic shifts likely to alter ALNY trajectory and sentiment.

4 , 11:14 AM
Alnylam gains competitive opening in ATTR CM after rival trial fails. Rival failure directly expands Alnylam market opportunity in ATTR CM and lifts revenue outlook.

3 , 8:19 PM
Rival trial failure shifts ATTR CM expectations potentially making Alnylam Pharmaceuticals (ALNY) appear undervalued. Competitor setback in ATTR CM may boost ALNY competitive standing and investor outlook.

9 Jul

3 qz.com, 7:14 AM
AstraZeneca stock fell 9% after Wainua heart drug trial failure. Wainua trial failure in ATTR space offers Alnylam moderate competitive gain.

6 Jul

4 , 11:55 AM
Alnylam's RNAi pipeline targets multiple rare diseases with late-stage candidates that could expand approved products, increase market reach, and support sustained revenue growth beyond current Onpattro and Givlaari sales. Pipeline success or delays directly reshape Alnylam's revenue base and valuation outlook.

3 Jul

3 , 7:59 AM
Alnylam Pharmaceuticals targets sustained long-term growth via RNAi drug pipeline expansion, regulatory progress, and commercial execution in rare disease markets. Pipeline and strategy updates may influence financials and positioning but effects remain balanced by execution risks and competition.

2 Jul

3 www.fool.com, 6:53 AM
Analysts forecast Alnylam Pharmaceuticals (ALNY) shares could rise 45%, backed by positive views on pipeline progress and market positioning. Analyst price targets create moderate short-term investor sentiment shifts for Alnylam without altering core operations.

3 , 2:17 AM
Komodo expands strategic partnership with Alnylam Pharmaceuticals. Expanded partnership may moderately support Alnylam operations and market positioning.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us